# Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

> **NCT04992247** · PHASE2 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** COVI-MSC
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04992247
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-02
- **Primary completion:** 2024-07
- **Final completion:** 2024-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sorrento Therapeutics filed for chapter 11 bankruptcy.
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04992247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04992247, "Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04992247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*